A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2.
Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile enterotoxin (mLT) in mice, their serum and lung fluid reacted with appropriate StxB. Mice vaccinated with Stx2B-His plus mLT had antibodies reacting Stx1B and showed the resistance to toxemia of Stx1 and Stx2. This is the first demonstration to get anti-Stx2B serum neutralizing both Stxs. These suggest that the nasal vaccination with Stx2B-His and mLT is effective for preventing toxemias by EHEC.
Tsuji
Takao
T
Department of Microbiology, Fujita Health University, School of Medicine, Toyoake, Aichi 470-1192, Japan. ttsuji@fujita-hu.ac.jp
Shimizu
Takeshi
T
Sasaki
Keiko
K
Tsukamoto
Kentaro
K
Arimitsu
Hideyuki
H
Ochi
Sadayuki
S
Shimizu
Toshiyasu
T
Taniguchi
Koki
K
Noda
Masatoshi
M
Neri
Paola
P
Mori
Hiroshi
H
D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology; D004927:Escherichia coli Infections / Q000276:immunology / Q000517:prevention & control*; D022361:Escherichia coli Vaccines / Q000276:immunology*; D008168:Lung / Q000276:immunology; D051379:Mice; D022622:Shiga Toxin 1 / Q000276:immunology*; D022641:Shiga Toxin 2 / Q000276:immunology*; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D022361:Escherichia coli Vaccines; D022622:Shiga Toxin 1; D022641:Shiga Toxin 2; D022223:Vaccines, Subunit